These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16302674)

  • 1. Review: intravenous immunoglobulin therapy and thromboembolic complications.
    Katz U; Shoenfeld Y
    Lupus; 2005; 14(10):802-8. PubMed ID: 16302674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboembolic complications of intravenous immunoglobulin treatment.
    Vucic S; Chong PS; Dawson KT; Cudkowicz M; Cros D
    Eur Neurol; 2004; 52(3):141-4. PubMed ID: 15479982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.
    Lidar M; Masarwa S; Rotman P; Carmi O; Rabinowicz N; Levy Y
    Immunol Res; 2018 Dec; 66(6):668-674. PubMed ID: 30565202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of intravenous immunoglobulin (IVIG) therapy.
    Katz U; Achiron A; Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
    Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
    Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
    Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
    Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
    Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
    Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.
    Dalakas MC
    Neurology; 1994 Feb; 44(2):223-6. PubMed ID: 8309562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin: adverse effects and safe administration.
    Orbach H; Katz U; Sherer Y; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolic complications following intravenous immunoglobulin therapy in immune-mediated neurological disorders.
    Chun W; Kim Y; Park SH; Choi SJ
    J Clin Neurosci; 2021 Aug; 90():311-316. PubMed ID: 34275568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature.
    Hefer D; Jaloudi M
    Ann Hematol; 2004 Oct; 83(10):661-5. PubMed ID: 15309520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study.
    Ramírez E; Romero-Garrido JA; López-Granados E; Borobia AM; Pérez T; Medrano N; Rueda C; Tong HY; Herrero A; Frías J
    Thromb Res; 2014 Jun; 133(6):1045-51. PubMed ID: 24731561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study.
    Rajabally YA; Kearney DA
    J Neurol Sci; 2011 Sep; 308(1-2):124-7. PubMed ID: 21679973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases.
    Elkayam O; Paran D; Milo R; Davidovitz Y; Almoznino-Sarafian D; Zeltser D; Yaron M; Caspi D
    Ann Rheum Dis; 2000 Jan; 59(1):77-80. PubMed ID: 10627434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
    Barsheshet A; Marai I; Appel S; Zimlichman E
    Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
    Sapir T; Blank M; Shoenfeld Y
    Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases.
    Katz U; Shoenfeld Y; Zandman-Goddard G
    Curr Pharm Des; 2011; 17(29):3166-75. PubMed ID: 21864262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record.
    Dalakas MC; Clark WM
    Neurology; 2003 Jun; 60(11):1736-7. PubMed ID: 12796522
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of intravenous immunoglobulin G in autoimmune hematologic disorders.
    Blanchette VS; Kirby MA; Turner C
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):72-82. PubMed ID: 1509297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases.
    Dalakas MC
    Neurology; 1998 Dec; 51(6 Suppl 5):S2-8. PubMed ID: 9851723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.